Notifications
Clear all
Topic starter
28/12/2020 9:54 pm
From https://cdrjournal.com/article/view/3829
Clinical trials for platinum-resistant recurrent ovarian cancer
| Identifier | Function | Phase | |
|---|---|---|---|
| Immune checkpoint inhibitor | |||
| Durvalumab | NCT03026062 | Programmed cell death ligand 1 inhibitor | 2 |
| NCT03699449 | 2 | ||
| NCT02431559 | 1/2 | ||
| NCT02764333 | 2 | ||
| NCT04019288 | 1/2 | ||
| NCT02963831 | 2 | ||
| NCT02811497 | 2 | ||
| Pembrolizumab | NCT02608684 | Targets programmed cell death protein 1 receptor | 2 |
| Atezolizumab | NCT03363867 | Targets programmed cell death ligand 1 (PD-L1) | 2 |
| TSR-042 | NCT03574779 | Anti-PD1 antibody | 2 |
| Tremelimumab | NCT02953457 | Activates the immune system by targeting CTLA-4 | 2 |
| NCT03026062 | 2 | ||
| Ipilimumab | NCT03508570 | Activates the immune system by targeting CTLA-4 | 1 |
| Avelumab | NCT02580058 | Targets the protein programmed death-ligand 1 (PD-L1) | 3 |
| Anti-angiogenic inhibitor | |||
| Apatinib | NCT04348032 | Vascular endothelial growth factor receptor-2 (VEGFR2) inhibitor | 2 |
| Cediranib | NCT03699449 | Vascular endothelial growth factor inhibitor | 2 |
| Anlotinib | NCT04376073 | c-MET/TIE-2/VEGFR inhibitor | 2 |
| Tivozanib | NCT01853644 | Oral VEGF receptor tyrosine kinase inhibitor | 2 |
| Bevacizumab | NCT03093155 | VEGF receptor tyrosine kinase inhibitor | 2 |
| Sevacizumab | NCT03763123 | VEGF receptor tyrosine kinase inhibitor | 1 |
| VB-111 | NCT03398655 | An anti-angiogenic gene therapy | 3 |
| Regorafenib | NCT02736305 | Dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition | 2 |
| Pazopanib | NCT01402271 | Selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumor growth and inhibits angiogenesis | 1/2 |
| PARP inhibitor | |||
| Olaparib | NCT02889900 | PARP inhibitor | 2 |
| NCT04633239 | 1 | ||
| NCT03117933 | 2 | ||
| NCT02898207 | 1 | ||
| NCT03161132 | 2 | ||
| NCT03699449 | 2 | ||
| NCT03314740 | 2 | ||
| NCT02502266 | 2/3 | ||
| Niraparib | NCT04376073 | PARP inhibitor | 2 |
| NCT03955471 | 2 | ||
| NCT04502602 | 1 | ||
| NCT03586661 | 1 | ||
| NCT04217798 | 2 | ||
| NCT03944902 | 1 | ||
| NCT01227941 | 1 | ||
| Rucaparib | NCT03552471 | PARP inhibitor | 1 |
| Talazoparib | NCT03330405 | PARP inhibitor | 2 |
| Other tyrosine kinase inhibitor | |||
| BAY1895344 | NCT04267939 | Ataxia-telangiectasia and Rad3 related protein (ATR) inhibitor | 1 |
| Prexasertib | NCT03414047 | CHK1 inhibitor | 2 |
| Adavosertib | NCT03579316 | WEE1 G2 checkpoint kinase (WEE1) inhibitor | 2 |
| Copanlisib | NCT03586661 | Phosphatidylinositol-3-kinase (PI3K) inhibitor | 1 |
| TP-0903 | NCT02729298 | Targets the AXL (derived from the Greek word “anexelekto”, meaning uncontrolled) receptor tyrosine kinase | 1 |
| AVB-S6-500 | NCT03639246 | Targets the AXL (derived from the Greek word “anexelekto”, meaning uncontrolled) receptor tyrosine kinase | 1/2 |
| Ixabepilone | NCT03093155 | Stabilizes microtubules | 2 |
| NCT02595892 | 2 | ||
| Cobimetinib | NCT03363867 | MEK inhibitor | 2 |
| NCT02101775 | 2 | ||
| Motolimod | NCT02431559 | Toll-like receptor 8 (TLR8) agonist | 1/2 |
| Entinostat | NCT03924245 | Benzamide histone deacetylase inhibitor | 1/2 |
This topic was modified 3 years ago by Daniel
